Skip to content

Design and development of 2,7-disubstituted 6-methoxyquinazolin-4 (3H)-ones as potential anti-cancer agents possibly through downregulation of Wnt/β-catenin/TCF4 signaling pathway.

Aug 2026 · Future Medicinal Chemistry · Vol 18, pp. 1-15 · 0 citations · 90 references
Medicine

TL;DR

Compound 42D represents a promising molecule as an anti-cancer agent against colon, hepatocellular, and gallbladder cancers targeting the Wnt/β-catenin/TCF4 signaling pathway.

Abstract

Aim

A novel series of 2,7-disubstituted 6-methoxyquinazolin-4(3H)-one derivatives were designed, synthesized, and evaluated for in-vitro anti-cancer potential.

Methods

Compounds were docked, synthesiazed and then evaluated for in vitro anti-cancer activity using the sulforhodamine B assay in HCT116 and HepG2 cells. Apoptosis induction was analyzed via morphological changes, Hoechst 33342, and Annexin V/PI staining. The effect on β-catenin/TCF‑mediated transcriptional activity was assessed by TOPFlash/FOPFlash assay, TCF4 and β-catenin protein expression by immunocytofluorescence, and Wnt target genes (like c-MYC and Cyclin D1) mRNA levels by RT-PCR against HCT116 cells. Furthermore, In vitro anti-cancer potential was evaluated against primary human gallbladder cancer cells.

Results

The derivatives showed favorable binding with the active site residues on β-catenin and have the potential to disrupt the β-catenin/TCF4 interaction. Most of them have comparable anti-cancer activity to imatinib mesylate. Compound 42D, one of the potent compounds (IC50: 3.89 μM in HCT116; 8.28 μM in HepG2), induced apoptosis, and significantly downregulated β-catenin/TCF4 signaling and downstream targets (c-Myc, Cyclin D1) in HCT116 cells and this could be one of the mechanisms by which it exerts its anti-cancer activity. It showed anti-cancer activity in primary gallbladder cancer cells (IC50: 7.26 μM).

Conclusion

Compound (42D) represents a promising molecule as an anti-cancer agent against colon, hepatocellular, and gallbladder cancers targeting the Wnt/β-catenin/TCF4 signaling pathway.

View source

Similar papers

Open access Sep 2026

Anilino-1,4-naphthoquinone derivatives exhibit antiproliferative, anti-inflammatory, and pro-apoptotic activities in LPS-stimulated SW480 colorectal cancer cells: In vitro and in silico studies.

Findings establish compound 12 as a promising lead candidate for the development of new anti-colorectal cancer agents and provide mechanistic insights into the interplay between COX-2 inhibition, inflammatory modulation, and apoptosis induction in inflammation-associated colorectal carcinogenesis.

Sakdiphong Punpai, Panupong Mahalapbutr, Panyakorn Taweechat et al. · 0 citations
Open access Sep 2026

Anti-proliferative and anti-inflammatory potential of 2-chloro-3-((4-hydroxyphenyl)amino)naphthalene-1,4-dione through targeting TNF-α/IL-8 and NF-κB signaling in HCT116 cancer cells: a comprehensive in silico docking and in vitro study

Findings suggest that compound 12 exerts anticancer activity through dual anti-inflammatory and pro-apoptotic mechanisms, possibly by modulating the NF-κB pathway, and may represent a promising lead candidate for further drug development against CRC.

Sakdiphong Punpai, Panupong Mahalapbutr, Panyakorn Taweechat et al. · 0 citations
Sep 2026

A Thieno[3,2-D] pyrimidine class of p110α/GDH1 dual inhibitor SBS-873 suppresses TNBC growth by inhibiting PI3K/mTOR signaling and inducing ferroptosis through glutathione depletion.

Findings identify SBS-873 as a first-in-class dual inhibitor targeting both p110α and GDH1, offering a promising therapeutic strategy that simultaneously disrupts proliferative signaling, metabolic adaptation, and metastatic potential in TNBC.

Biswajit Dey, Essha Chatterjee, Sivkan Kaur Nanda et al. · 0 citations
Open access Aug 2026

1-Butylindoline-2,3-dione derivatives as potent VEGFR-2 inhibitors: synthesis, mechanistic anticancer studies, and molecular dynamics simulations

Compound 6b is identified as a promising lead candidate for further development as a VEGFR-2-targeted anticancer agent and stable backbone behavior, regulated ligand fluctuations, preserved structural compactness, and sustained hydrogen bonding within the 6b-VEGFR-2 complex are identified.

Mohamed El-Naggar, Hend I Abdelaal, Mohamed E Albakri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.